FIH Live Trial Status Matrix

FIH Live Trial Status — 可 referral 查詢表

從 AACR 2026 FIH 章節提到的 abstracts 抽出 NCT IDs，對 ClinicalTrials.gov 拉即時狀態。 門診看到病人時查這頁，知道哪個 trial 還在收、在哪個 site、目前階段。 每週重跑 scripts/fih_nct_status.py 更新。

RECRUITING (86)

NCT03476681 · Study of NEO-201 in Solid Tumors Expansion Cohorts

Phase: PHASE1, PHASE2 · Sponsor: Precision Biologics, Inc · Enrollment: 121 · Start: 2019-01-18 · Primary completion: 2028-01-15

Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer Interventions: NEO-201 in combination with pembrolizumab Countries: United States

Cited in AACR 2026:

• AB#7933 · NEO-201-recognized truncated Core 1 O-glycans represent a new target for CAR-NK · Joseph Clara · Alternative Cell Type and in Situ Cell Therapies

NCT03942328 · Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With I

Phase: PHASE1, PHASE2 · Sponsor: Mayo Clinic · Enrollment: 85 · Start: 2019-09-19 · Primary completion: 2029-08-31

Conditions: Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma Interventions: Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine, Therapeutic Autologous Dendritic Cells Countries: United States

Cited in AACR 2026:

• AB#6238 · Radiation-dendritic cell combination therapy drives systemic cellular immune shi · Melody Wu, BS · Biomarkers Predictive of Therapeutic Benefit 4

NCT04196413 · GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Gliom

Phase: PHASE1 · Sponsor: Stanford University · Enrollment: 97 · Start: 2020-06-04 · Primary completion: 2028-07-31

Conditions: Glioma of Spinal Cord, Glioma of Brainstem Interventions: GD2 CAR T cells, Fludarabine, Cyclophosphamide, Rituximab Countries: United States

Cited in AACR 2026:

• AB#5179 · Longitudinal single-cell atlas of GD2-CAR T cell therapy in H3K27M-mutant diffus · Yiyun Chen, PhD · Clinical Correlates of Immunotherapy

NCT04495296 · A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST

Phase: PHASE1, PHASE2 · Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. · Enrollment: 320 · Start: 2020-08-13 · Primary completion: 2026-06-25

Conditions: Advanced Cancer Interventions: TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin Countries: China

Cited in AACR 2026:

• AB#3413 · Characterization of osemitamab in pancreatic cancer models and patients · Yi Gu, PhD · Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates 1

NCT04588922 · Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients Wit

Phase: PHASE1, PHASE2 · Sponsor: Sellas Life Sciences Group · Enrollment: 160 · Start: 2021-05-10 · Primary completion: 2026-12-30

Conditions: Hematologic Malignancies Interventions: SLS009, venetoclax, azacitidine Countries: China, United States

Cited in AACR 2026:

• AB#8216 · Tambiciclib (SLS009), a CDK9 inhibitor, promotes apoptosis and suppresses MCL-1 · Elizabeth Trull, BS · Cell Death Pathways and Treatment

NCT04594642 · A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

Phase: PHASE1 · Sponsor: AstraZeneca · Enrollment: 317 · Start: 2021-03-02 · Primary completion: 2028-04-19

Conditions: B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Interventions: AZD0486 IV Countries: Australia, Japan, South Korea, Taiwan, United States

Cited in AACR 2026:

• AB#2044 · Exposure-response analysis and quantitative systems pharmacology modeling for an · Xu Zhu · Quantitative Pharmacology and Translational Modeling

NCT04855695 · Avo In R/R And Previously Untreated MCL

Phase: PHASE1, PHASE2 · Sponsor: Austin I Kim · Enrollment: 72 · Start: 2021-07-02 · Primary completion: 2027-06-30

Conditions: Mantle Cell Lymphoma, Refractory Lymphoma Interventions: Acalabrutinib, Venetoclax, Obinutuzumab Countries: United States

Cited in AACR 2026:

• AB#3958 · Baseline single-cell mass distributions correlate with clinical response to acal · Mingzeng Zhang, MD;PhD · Biomarkers Predictive of Therapeutic Benefit 3

NCT04947189 · Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Trip

Phase: PHASE1, PHASE2 · Sponsor: St Vincent’s Hospital, Sydney · Enrollment: 65 · Start: 2022-11-01 · Primary completion: 2026-07

Conditions: Triple Negative Breast Cancer Interventions: Seviteronel-D (Seivteronel in combination with dexamethasone), Docetaxel Countries: Australia

Cited in AACR 2026:

• AB#9889 · Androgen receptor inhibition to overcome taxane resistance in AR-positive metast · Jia (Jenny) Liu, MD;PhD · First-in-Human Phase I Clinical Trials

NCT05067283 · A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Phase: PHASE1 · Sponsor: Merck Sharp & Dohme LLC · Enrollment: 830 · Start: 2021-12-17 · Primary completion: 2030-02-25

Conditions: Advanced Solid Tumors Interventions: Calderasib, Pembrolizumab, carboplatin, pemetrexed, cetuximab, oxaliplatin Countries: Argentina, Australia, Canada, Chile, China, Denmark, Israel, Italy

Cited in AACR 2026:

• AB#1433 · Effect of the KRAS G12C inhibitor MK-1084 on circulating tumor DNA levels in par · Carlos Rojas, MD · Biomarkers Predictive of Therapeutic Benefit 1

NCT05118789 · A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors H

Phase: PHASE1, PHASE2 · Sponsor: Nuvalent Inc. · Enrollment: 359 · Start: 2022-01-04 · Primary completion: 2027-12-31

Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor Interventions: Zidesamtinib (NVL-520) Countries: Australia, Belgium, Canada, France, Germany, Italy, Japan, Netherlands

Cited in AACR 2026:

• AB#10586 · Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotre · Geoffrey Liu, MD · Phase II Clinical Trials

NCT05141253 · Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid T

Phase: EARLY_PHASE1 · Sponsor: Tongji Hospital · Enrollment: 24 · Start: 2022-01-12 · Primary completion: 2023-11-01

Conditions: Cancer Interventions: RD133 Countries: China

Cited in AACR 2026:

• AB#387 · AQP3 NOT gating mitigates lethal on-target off-tumor pulmonary toxicity of MSLN- · Minghua Xiang, PhD · CAR T Cell Functional Enhancement

NCT05227326 · AOH1996 for the Treatment of Refractory Solid Tumors

Phase: PHASE1 · Sponsor: City of Hope Medical Center · Enrollment: 92 · Start: 2022-08-12 · Primary completion: 2029-09-13

Conditions: Refractory Malignant Solid Neoplasm, Osteosarcoma, Leiomyosarcomas, Synovial Sarcomas, Ovarian Cancer, Non-Small Cell Lung Cancer Interventions: PCNA Inhibitor AOH1996 Countries: United States

Cited in AACR 2026:

• AB#7656 · Development of hydrophilic and metabolically stable heterocyclic AOH1996 analogu · Pouya Haratipour, PhD · New Ligands and Inhibitors

NCT05244551 · A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With A

Phase: PHASE1 · Sponsor: Abbisko Therapeutics Co, Ltd · Enrollment: 85 · Start: 2022-06-30 · Primary completion: 2025-04-30

Conditions: Solid Tumor Interventions: ABSK061 Countries: China, United States

Cited in AACR 2026:

• AB#2229 · Circulating tumor DNA (ctDNA)-based profiling of acquired resistance to the fibr · Nannan Zhang, PhD · Liquid Biopsies: Circulating Nucleic Acids 4

NCT05351502 · A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Soli

Phase: PHASE1 · Sponsor: Beyond Air Inc. · Enrollment: 38 · Start: 2022-08-14 · Primary completion: 2025-05-30

Conditions: Cancer Interventions: Nitric Oxide 25,000 ppm, Nitric Oxide 50,000 ppm, Nitric Oxide 100,000 ppm, Nitric Oxide selected dose Countries: Israel

Cited in AACR 2026:

• AB#6320 · A phase 1 study of intratumoral ultra-high concentration nitric oxide (UNO) gas · Amichay Meirovitz, MD · Innovative Therapeutic Modalities and Translational Platforms

NCT05378425 · A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155),

Phase: PHASE1 · Sponsor: Nectin Therapeutics Ltd · Enrollment: 90 · Start: 2022-09-01 · Primary completion: 2025-12

Conditions: Cancer, Tumor, Solid, Advanced Solid Tumor, Metastatic Cancer, Locally Advanced Solid Tumor Interventions: NTX-1088, Pembrolizumab Countries: Israel, Poland, United States

Cited in AACR 2026:

• AB#2319 · NTX1088 demonstrates the first-ever clinical restoration of DNAM1, defining a no · Yaron Daniely, Unknown · Immune Checkpoint Blockade

NCT05379595 · A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Par

Phase: PHASE1, PHASE2 · Sponsor: Janssen Research & Development, LLC · Enrollment: 225 · Start: 2022-07-29 · Primary completion: 2027-04-27

Conditions: Advanced or Metastatic Colorectal Cancer Interventions: Amivantamab IV, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan, Amivantamab Countries: Belgium, Canada, China, Germany, Italy, Malaysia, Puerto Rico, South Korea

Cited in AACR 2026:

• AB#10295 · OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in comb · Bing Xia · Phase II and Phase III Clinical Trials in Progress

NCT05379985 · Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in R

Phase: PHASE1, PHASE2 · Sponsor: Revolution Medicines, Inc. · Enrollment: 754 · Start: 2022-05-31 · Primary completion: 2027-05-31

Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors Interventions: RMC-6236 Countries: United States

Cited in AACR 2026:

• AB#10234 · Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastat · Eileen O’Reilly, MD · Late-Breaking Research: Clinical Research 3
• AB#11041 · Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (P · Brian Wolpin, MD;MPH · Minisymposium: Late-Breaking Research
• AB#10387 · RASolve 301: A Phase 3 study of daraxonrasib (RMC-6236) vs. docetaxel in patient · Ferdinandos Skoulidis, MD;PhD · Phase II and Phase III Clinical Trials in Progress

NCT05405595 · ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Phase: PHASE1, PHASE2 · Sponsor: Adagene Inc · Enrollment: 186 · Start: 2022-06-15 · Primary completion: 2026-10-31

Conditions: Advanced/Metastatic Solid Tumors Interventions: ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab), Standard of care (Fruquintinib) Countries: China, South Korea, United States

Cited in AACR 2026:

• AB#10371 · Ph1b evaluation of ADG126 (muzastotug, an anti-CTLA-4 masking antibody) pembroli · Jiping Zha, MD;PhD · Phase I Clinical Trials in Progress

NCT05528055 · A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Ad

Phase: PHASE1 · Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. · Enrollment: 122 · Start: 2022-05-18 · Primary completion: 2027-10

Conditions: Solid Tumor, Non Hodgkin Lymphoma Interventions: SCR-6920 capsule, SCR-6920 capsule, SCR-6920 capsule, SCR-6920 capsule Countries: China

Cited in AACR 2026:

• AB#3579 · PRMT5 inhibitor SCR-6920 downregulates HIF-1α and exhibits synergistic anti · Zhengtao Li, PhD · New Ligands and Inhibitors

NCT05553782 · Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

Phase: EARLY_PHASE1 · Sponsor: Brigham and Women’s Hospital · Enrollment: 30 · Start: 2023-11-01 · Primary completion: 2029-04-01

Conditions: Salivary Gland Cancer, Adenoid Cystic Carcinoma of the Salivary Gland, Squamous Cell Carcinoma of Head and Neck, Head and Neck Cancer Interventions: Implantable Microdevice (IMD) Countries: United States

Cited in AACR 2026:

• AB#11204 · Phase I study of intratumoral microdevices reveals heterogenous immune and apopt · Fanni Santa, MD · First-in-Human Phase I Clinical Trials

NCT05636618 · Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive

Phase: PHASE1, PHASE2 · Sponsor: Perspective Therapeutics · Enrollment: 260 · Start: 2023-09-27 · Primary completion: 2029-11-26

Conditions: Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma Interventions: [203Pb]VMT-α-NET, [212Pb]VMT-α-NET Countries: United States

Cited in AACR 2026:

• AB#11081 · [²¹²Pb]VMT-a-NET in advanced SSTR2+ neuroendocrine tumors: safety and · Thorvardur Halfdanarson, MD · Phase I Clinical Trials in Progress

NCT05714072 · A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

Phase: PHASE1 · Sponsor: Memorial Sloan Kettering Cancer Center · Enrollment: 18 · Start: 2023-01-25 · Primary completion: 2027-01

Conditions: Myelofibrosis Due to and Following Polycythemia Vera Interventions: Ruxolitinib, Abemaciclib Countries: United States

Cited in AACR 2026:

• AB#10169 · The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates · Brian Chernak, MD · Phase I Clinical Trials

NCT05720117 · A Study of PYX-201 in Advanced Solid Tumors

Phase: PHASE1 · Sponsor: Pyxis Oncology, Inc · Enrollment: 330 · Start: 2023-03-14 · Primary completion: 2026-07

Conditions: Solid Tumor, Advanced Solid Tumor Interventions: PYX-201 Countries: Belgium, Spain, United Kingdom, United States

Cited in AACR 2026:

• AB#5192 · Mouse analog of micvotabart pelidotin, an antibody-drug conjugate targeting extr · Anthony Rodriguez, MS;PhD · Antibody Technologies and Platforms 2

NCT05720130 · Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prosta

Phase: PHASE1, PHASE2 · Sponsor: AdvanCell Pty Limited · Enrollment: 100 · Start: 2023-03-15 · Primary completion: 2029-01-31

Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer Interventions: [²¹²Pb]Pb-ADVC001 (Phase 1b), [²¹²Pb]Pb-ADVC001 (Phase 2a) Countries: Australia

Cited in AACR 2026:

• AB#2714 · Mechanistic insights into the anti-tumor activity of ²¹²Pb-PSMA r · Peter Skingley · Effects of Ionizing Radiation on Normal Tissues and FLASH Radiation Research

NCT05763992 · Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherap

Phase: PHASE2 · Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Enrollment: 145 · Start: 2023-05-15 · Primary completion: 2025-05-15

Conditions: Breast Cancer, Triple Negative Breast Cancer, Dietary Exposure, Fasting Interventions: Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B) Countries: Italy

Cited in AACR 2026:

• AB#5938 · Fasting induces ferroptosis by modulating lipid metabolism in breast cancer · Claudio Vernieri, MD;PhD · Metabolic Regulation in Breast and Gynecologic Cancers

NCT05791448 · AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metast

Phase: PHASE1 · Sponsor: University of Southern California · Enrollment: 36 · Start: 2023-03-29 · Primary completion: 2026-03-29

Conditions: Advanced Cholangiocarcinoma, Advanced Hepatocellular Carcinoma, Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Refractory Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v8 Interventions: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, RNA Transcription Modulator AU-409 Countries: United States

Cited in AACR 2026:

• AB#10621 · Early clinical activity and tumor transcriptional modulation of AU409, a first-i · Anthony El-Khoueiry, MD · First-in-Human Phase I Clinical Trials

NCT05836324 · A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic So

Phase: PHASE1 · Sponsor: Incyte Corporation · Enrollment: 408 · Start: 2023-07-24 · Primary completion: 2027-01-13

Conditions: Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors Interventions: INCA33890, bevacizumab, FOLFIRI, FOLFOX, Cetuximab Countries: Denmark, France, Italy, Japan, Spain, Switzerland, United Kingdom, United States

Cited in AACR 2026:

• AB#295 · Pharmacodynamic biomarkers of TGFβR2xPD-1 bispecific antibody INCA33890 in · Michael Smith, PhD · Immunomodulatory Agents and Interventions

NCT05848739 · A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

Phase: PHASE1 · Sponsor: Sapience Therapeutics · Enrollment: 130 · Start: 2023-06-05 · Primary completion: 2026-05-31

Conditions: Colon Cancer, Metastatic Colon Cancer Interventions: ST316, FOLFIRI regimen & bevacizumab, Fruquintinib, Lonsurf & bevacizumab Countries: United States

Cited in AACR 2026:

• AB#4112 · Antagonism of β-Catenin/BCL9 interaction suppresses polymorphonuclear myelo · Jim Rotolo, PhD · Oncogenic Pathways and Cancer Immunity

NCT05873244 · CXD101 in Immunotherapy-related Liver Cancer

Phase: PHASE2 · Sponsor: Stephen Chan Lam · Enrollment: 44 · Start: 2023-08-21 · Primary completion: 2026-12-30

Conditions: HCC Interventions: Zabadinostat (CXD101) and Geptanolimab, Lenvatinib and Sorafenib Countries: Hong Kong

Cited in AACR 2026:

• AB#986 · Deciphering the function of lipid-associated macrophages in immunotherapy resist · Xiaohang Long, BS;M Phil;PhD · Modifiers of Inflammation and the Tumor Microenvironment

NCT05933265 · Study of LP-184 in Patients With Advanced Solid Tumors

Phase: PHASE1, PHASE2 · Sponsor: Lantern Pharma Inc. · Enrollment: 175 · Start: 2023-06-09 · Primary completion: 2025-02-28

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma Interventions: LP-184, Spironolactone, Olaparib Countries: United States

Cited in AACR 2026:

• AB#10019 · Data-driven characterization of platelet count and alanine aminotransferase dyna · Jianli Zhou · Phase 0 and First-in-Human Phase I Clinical Trials

NCT06016920 · Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell

Phase: PHASE1, PHASE2 · Sponsor: Nykode Therapeutics ASA · Enrollment: 51 · Start: 2023-12-19 · Primary completion: 2027-09

Conditions: HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC Interventions: VB10.16, Pembrolizumab Countries: Czechia, France, Germany, Hungary, Norway, Poland, Spain, United Kingdom

Cited in AACR 2026:

• AB#9744 · Immunogenicity of the therapeutic HPV16-specific cancer vaccine abipapogene suva · Ingvild Leikfoss · Phase I Clinical Trials

NCT06026605 · A Dose Escalation and Dose Expansion Trial of WTX212A in the Treatment of Patients with Ad

Phase: EARLY_PHASE1 · Sponsor: Zhejiang University · Enrollment: 44 · Start: 2023-08-25 · Primary completion: 2026-08-30

Conditions: Unresectable or Metastatic Advanced Solid Tumors Interventions: WTX212A Countries: China

Cited in AACR 2026:

• AB#2299 · A first-in-class Erythrocyte-anti-PD-1 conjugate overcomes immunotherapy resista · Xiaoqian Nie, BS · Adoptive Cell Therapy 1

NCT06066138 · A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Phase: PHASE1 · Sponsor: National Cancer Institute (NCI) · Enrollment: 30 · Start: 2025-11-04 · Primary completion: 2027-01-31

Conditions: Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Locally Advanced Small Cell Lung Cancer, Metastatic Small Cell Lung Cancer Interventions: Atezolizumab Countries: United States

Cited in AACR 2026:

• AB#9768 · Toward personalized atezolizumab dosing by therapeutic drug monitoring · Hoyoung Maeng, MD;MS · Phase I and Phase II Clinical Trials in Progress

NCT06161025 · A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade

Phase: PHASE2, PHASE3 · Sponsor: Daiichi Sankyo · Enrollment: 860 · Start: 2024-02-27 · Primary completion: 2028-02-29

Conditions: Solid Cancer Interventions: R-DXd, Paclitaxel, Topotecan, PLD Countries: Australia, Canada, China, Czechia, France, Germany, Italy, Japan

Cited in AACR 2026:

• AB#367 · Pharmacokinetic-tumor growth inhibition modeling of raludotatug deruxtecan (R-DX · YoungJun Yoo, Pharm D · Quantitative Pharmacology and Translational Modeling

NCT06171750 · Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Phase: PHASE1 · Sponsor: Ankyra Therapeutics, Inc · Enrollment: 97 · Start: 2024-01-19 · Primary completion: 2027-04

Conditions: Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor Interventions: tolododekin alfa, Cemiplimab Countries: Canada, United States

Cited in AACR 2026:

• AB#10416 · Immune escape via myeloid-derived suppressor cells in solid tumor cancer patient · Wiem Lassoued, PhD · Phase 0 and First-in-Human Phase I Clinical Trials

NCT06179069 · A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Phase: PHASE1 · Sponsor: Zai Lab (Shanghai) Co., Ltd. · Enrollment: 339 · Start: 2024-01-23 · Primary completion: 2027-05-30

Conditions: SCLC Interventions: ZL-1310, Atezolizumab, Carboplatin Countries: China, Spain, United States

Cited in AACR 2026:

• AB#10362 · Intracranial activity of ZL-1310, a DLL3-targeted ADC, in patients with previous · Pingkuan Zhang, MD · Phase I Clinical Trials

NCT06205849 · Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Local

Phase: PHASE1 · Sponsor: University of California, San Diego · Enrollment: 18 · Start: 2024-06-25 · Primary completion: 2027-08

Conditions: Pancreatic Cancer Interventions: IRE + intratumoral mitazalimab (CD40 antibody) injection, NanoKnife Countries: United States

Cited in AACR 2026:

• AB#9847 · Irreversible electroporation (IRE) with intratumoral CD40 antibody increases T-c · Rebekah White, MD · Phase I Clinical Trials in Progress

NCT06224387 · CTS2190 Phase I /II Clinical Study in Patients

Phase: PHASE1, PHASE2 · Sponsor: CytosinLab Therapeutics Co., Ltd. · Enrollment: 224 · Start: 2023-06-26 · Primary completion: 2025-07-31

Conditions: Solid Tumors, Pancreatic Cancer, Non-small Cell Lung Cancer, Triple-negative Breast Cancer Interventions: CTS2190 capsules Countries: China

Cited in AACR 2026:

• AB#1874 · The MTA-cooperative PRMT5 inhibitor CTS3497 alone and in synergy with mechanism- · Yilin Liu, PhD · Epigenetic Modulators 1
• AB#2235 · CTS2190, a first-in-class PRMT1 inhibitor in phase I/II clinical development, de · Hui Shi, MS · Epigenetic Modulators 1

NCT06240728 · A Study of NPX887 for Participants With Solid Tumors Known to Express B7-H7/HHLA2

Phase: PHASE1 · Sponsor: NextPoint Therapeutics, Inc. · Enrollment: 144 · Start: 2024-01-22 · Primary completion: 2027-08

Conditions: Metastatic Malignant Neoplasm Interventions: NPX887 Countries: South Korea, United States

Cited in AACR 2026:

• AB#8324 · Investigating the transcriptomic signature of B7-H7-mediated activation of NK ce · Michael Gomez, BA · Immune Checkpoint Blockade

NCT06258304 · A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or

Phase: PHASE1 · Sponsor: GigaGen, Inc. · Enrollment: 60 · Start: 2024-05-08 · Primary completion: 2026-04

Conditions: Advanced or Metastatic Solid Tumor Malignancies Interventions: GIGA-564, GIGA-564 Countries: United States

Cited in AACR 2026:

• AB#9733 · Preliminary phase 1a/1b results of GIGA-564, a novel intratumoral Treg-depleting · James Gulley, MD;PhD · Phase 0 and First-in-Human Phase I Clinical Trials

NCT06332430 · Intratumoral CAN2109 in Subjects With Solid Tumors

Phase: PHASE1 · Sponsor: Canwell Biotech Limited · Enrollment: 27 · Start: 2024-05-28 · Primary completion: 2025-05-30

Conditions: Solid Tumor, Lymphoma Interventions: CAN2109 Countries: China

Cited in AACR 2026:

• AB#10283 · A phse 1 study of CAN2109, a novel,long-acting, tumor-retained, immunoegenic cel · Jiancheng Huang, PhD · Phase I Clinical Trials in Progress

NCT06374485 · Study of AU409 Capsule in Advanced Hepatocellular Carcinoma Patients Who Failed Standard T

Phase: PHASE1 · Sponsor: Lee’s Pharmaceutical Limited · Enrollment: 18 · Start: 2024-05-21 · Primary completion: 2025-12-28

Conditions: Advanced Hepatocellular Carcinoma Interventions: AU409 Countries: China

Cited in AACR 2026:

• AB#10621 · Early clinical activity and tumor transcriptional modulation of AU409, a first-i · Anthony El-Khoueiry, MD · First-in-Human Phase I Clinical Trials

NCT06380660 · Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

Phase: PHASE1, PHASE2 · Sponsor: Acerand Therapeutics (Shanghai) Limited · Enrollment: 298 · Start: 2024-03-22 · Primary completion: 2028-12-21

Conditions: Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Breast Cancer, Prostate Cancer Interventions: ACE-86225106 tablet Countries: China

Cited in AACR 2026:

• AB#10592 · Updated results from a first-in-human phase 1,2 study of ACE-106, a highly selec · Kuo-Long Yu, PhD · First-in-Human Phase I Clinical Trials

NCT06399419 · CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced

Phase: PHASE1 · Sponsor: Osel, Inc. · Enrollment: 28 · Start: 2024-06-19 · Primary completion: 2026-10-19

Conditions: Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma Interventions: Biospecimen Collection, Bone Scan, CBM588 Capsules, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging Countries: United States

Cited in AACR 2026:

• AB#8693 · Microbiome modulation via CBM588 dampens T cell exhaustion in patients with meta · Colt Egelston, BS;PhD · Clinical Correlates of Immunotherapy

NCT06400472 · A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

Phase: PHASE1 · Sponsor: Eli Lilly and Company · Enrollment: 495 · Start: 2024-05-20 · Primary completion: 2027-02

Conditions: Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm Interventions: LY4170156, bevacizumab, carboplatin, Itraconazole, pembrolizumab Countries: Australia, France, Italy, Japan, South Korea, Spain, United States

Cited in AACR 2026:

• AB#623 · LY4170156, an antibody-drug conjugate targeting folate receptor alpha, exhibits · Zhaohai Lu, BS;MS · Engineering the Next Wave of Antibody-Based Cancer Therapeutics

NCT06402201 · First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid T

Phase: PHASE1 · Sponsor: CDR-Life AG · Enrollment: 42 · Start: 2024-05-24 · Primary completion: 2026-06-30

Conditions: Select Advanced Solid Tumors Interventions: CDR404 Countries: Belgium, Denmark, Italy, Spain, United Kingdom, United States

Cited in AACR 2026:

• AB#10393 · Mechanistic insights into the pharmacology of CDR609 support high potential as a · Athanasia Dasargyri · Late-Breaking Research: Immunology 3

NCT06445062 · Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase: PHASE1, PHASE2 · Sponsor: Revolution Medicines, Inc. · Enrollment: 1130 · Start: 2024-05-24 · Primary completion: 2027-05-15

Conditions: Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma Interventions: RMC-6236, mFOLFOX6 regimen, bevacizumab, mFOLFIRINOX regimen, cetuximab, gemcitabine Countries: United States

Cited in AACR 2026:

• AB#11041 · Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (P · Brian Wolpin, MD;MPH · Minisymposium: Late-Breaking Research

NCT06456892 · Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen

Phase: PHASE1, PHASE2 · Sponsor: Sun Yat-sen University · Enrollment: 82 · Start: 2024-06-06 · Primary completion: 2026-06-06

Conditions: Rhabdomyosarcoma, Pediatric Cancer Interventions: Pucotenlimab Countries: China

Cited in AACR 2026:

• AB#9930 · Safety and efficacy of pucotenlimab combined with standard chemotherapy regimens · Yizhuo Zhang, PhD · Phase I Clinical Trials

NCT06465199 · Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Phase: PHASE1, PHASE2 · Sponsor: Milton S. Hershey Medical Center · Enrollment: 289 · Start: 2026-04-28 · Primary completion: 2033-02

Conditions: Atypical Teratoid/Rhabdoid Tumor, Embryonal Tumor With Multilayered Rosettes, Ewing Sarcoma, Diffuse Intrinsic Pontine Glioma, Osteosarcoma, Neuroblastoma Interventions: Eflornithine (DFMO), AMXT 1501 Dicaprate Countries: United States

Cited in AACR 2026:

• AB#9834 · Clinical trial in progress: BCC020 a dose escalation study using difluoromethylo · Giselle Saulnier Sholler, MD · Phase I and Phase II Clinical Trials in Progress

NCT06484062 · Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Out

Phase: PHASE1 · Sponsor: National Cancer Institute (NCI) · Enrollment: 54 · Start: 2025-08-15 · Primary completion: 2028-06-01

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia Interventions: Biospecimen Collection, Bone Marrow Aspiration, Cirtuvivint, Decitabine and Cedazuridine, Echocardiography Test, Multigated Acquisition Scan Countries: United States

Cited in AACR 2026:

• AB#1779 · The pan-CLK DYRK inhibitor SM09419 prolongs animal survival times in a subset of · Xin (Alice) Zhai, PhD · Mechanistic Insights for Targeted Therapies in Pediatric Cancer

NCT06536400 · Phase I Study of HSK42360 in Solid Tumors With BRAF V600 Mutation

Phase: PHASE1 · Sponsor: Haisco Pharmaceutical Group Co., Ltd. · Enrollment: 316 · Start: 2024-06-25 · Primary completion: 2026-08-30

Conditions: Solid Tumors Interventions: HSK42360 Countries: China

Cited in AACR 2026:

• AB#10198 · Novel brain-penetrant BRAF paradox breaker HSK42360 demonstrates promising antit · Shidong Gao · Minisymposium: Late-Breaking Research

NCT06541262 · Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tum

Phase: PHASE1, PHASE2 · Sponsor: Milton S. Hershey Medical Center · Enrollment: 104 · Start: 2024-10-30 · Primary completion: 2030-11-01

Conditions: Neuroblastoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Liposarcoma Interventions: Silmitasertib, Irinotecan, Temozolomide, Vincristine Countries: Canada, United States

Cited in AACR 2026:

• AB#10704 · Clinical trial in progress: BCC021 Phase I/II study of Silmitasertib (CX-4945) i · Chandrika Behura, MD · Phase I and Phase II Clinical Trials in Progress

NCT06587295 · Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With P

Phase: PHASE1 · Sponsor: National Cancer Centre, Singapore · Enrollment: 40 · Start: 2025-01-15 · Primary completion: 2026-12

Conditions: Advanced Solid Tumor, Metastatic Solid Tumor Interventions: Intramuscular ACM-CpG Monotherapy (Escalation), Intramuscular ACM-CpG Monotherapy (Expansion) Countries: Singapore

Cited in AACR 2026:

• AB#8162 · ACM-CpG, a polymersome-delivered TLR9 agonist, elicits rapid and broad immune ac · Amit Jain, PhD · Molecular Targeted Therapy

NCT06606990 · Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic

Phase: PHASE1 · Sponsor: National Cancer Institute (NCI) · Enrollment: 40 · Start: 2025-07-01 · Primary completion: 2026-12-31

Conditions: Metastatic Malignant Solid Neoplasm Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Pidnarulex Countries: United States

Cited in AACR 2026:

• AB#10408 · Pilot study of pidnarulex pharmacodynamics in patients with advanced solid tumor · Jibran Ahmed, MD · Phase I and Phase II Clinical Trials in Progress

NCT06645808 · PET-imaging of Two Vartumabs in Patients With Solid Tumors

Phase: EARLY_PHASE1 · Sponsor: Var2 Pharmaceuticals · Enrollment: 32 · Start: 2024-12-10 · Primary completion: 2026-08

Conditions: Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma, Chondrosarcoma, Lung Carcinoma Interventions: 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan Countries: Netherlands

Cited in AACR 2026:

• AB#11075 · Clinical validation of a first-in-class pan-cancer antibody Vartumab targeting o · Mads Daugaard, PhD · Phase 0 and First-in-Human Phase I Clinical Trials

NCT06650566 · Study of LM-299 in Subjects Advanced Malignant Tumors

Phase: PHASE1, PHASE2 · Sponsor: LaNova Medicines Limited · Enrollment: 108 · Start: 2024-10-09 · Primary completion: 2026-12

Conditions: Malignant Tumors Interventions: LM-299 Countries: Australia, China

Cited in AACR 2026:

• AB#10332 · Preliminary results from the first-in-human study of MK-2010, a PD-1×VEGF b · Jennifer Pawlowski · First-in-Human Phase I Clinical Trials

NCT06695845 · A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Phase: PHASE2 · Sponsor: Jazz Pharmaceuticals · Enrollment: 200 · Start: 2025-01-14 · Primary completion: 2026-12-31

Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer Interventions: Zanidatamab Countries: South Korea, United States

Cited in AACR 2026:

• AB#10314 · DiscovHER PAN-206: Phase 2 tumor-agnostic study of zanidatamab in patients with · Vivek Subbiah, MD · Phase II and Phase III Clinical Trials in Progress

NCT06716138 · A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tum

Phase: PHASE1 · Sponsor: Avistone Biotechnology Co., Ltd. · Enrollment: 96 · Start: 2025-03-06 · Primary completion: 2027-12-30

Conditions: Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration Interventions: ANS03 Countries: China, United States

Cited in AACR 2026:

• AB#11212 · A phase I study of the type II ROS1 TRK inhibitor ANS03 in ROS1 fusion-positive · Shengxiang Ren · First-in-Human Phase I Clinical Trials

NCT06719362 · A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monot

Phase: PHASE1 · Sponsor: Providence Health & Services · Enrollment: 110 · Start: 2025-06-17 · Primary completion: 2028-02

Conditions: Advanced Solid Tumors Interventions: M3T01, Pembrolizumab, Chemoradiation, FOLFOX regimen Countries: United States

Cited in AACR 2026:

• AB#10510 · Interim results of a phase I clinical trial evaluating Fas ligand (FasL) blockin · Matthew Taylor, MD · Phase 0 and First-in-Human Phase I Clinical Trials

NCT06725758 · A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumo

Phase: PHASE1, PHASE2 · Sponsor: Orion Corporation, Orion Pharma · Enrollment: 315 · Start: 2023-10-26 · Primary completion: 2027-12-31

Conditions: Solid Tumours Interventions: ODM-212 Countries: United Kingdom

Cited in AACR 2026:

• AB#5835 · Ex vivo trial of ODM-212, a novel pan-TEAD inhibitor, in patients with pr · Juha Rantala, PhD · Molecular Targets 1

NCT06761651 · A Study of TAVO412 in Patients with Cancer (TAVO412)

Phase: PHASE1 · Sponsor: Tavotek Biotherapeutics · Enrollment: 50 · Start: 2023-12-20 · Primary completion: 2026-01-01

Conditions: Cancer Interventions: TAVO412 Countries: China

Cited in AACR 2026:

• AB#10261 · Preliminary clinical results of TAVO412, an anti-EGFR/cMET/VEGF multispecific an · Mark Chiu, PhD · First-in-Human Phase I Clinical Trials

NCT06803875 · Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

Phase: PHASE1, PHASE2 · Sponsor: Roberto Chiarle · Enrollment: 42 · Start: 2025-01-31 · Primary completion: 2027-12-31

Conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma, High-risk Neuroblastoma Interventions: Autologous hALK.CAR T cells Countries: United States

Cited in AACR 2026:

• AB#1473 · ALK expression identifies a therapeutically targetable subset of Merkel cell car · Alessandro Gasparetto, MD · CAR T Cell Targets and TME Reprogramming

NCT06819735 · Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor

Phase: PHASE1, PHASE2 · Sponsor: Domain Therapeutics Australia Pty Ltd · Enrollment: 125 · Start: 2025-06-25 · Primary completion: 2027-09

Conditions: Advanced Solid Tumors Interventions: DT-7012, Immune checkpoint inhibitor Countries: Australia, France

Cited in AACR 2026:

• AB#9616 · Design and rationale of DOMISOL, a first-in-human Phase I/II study of DT-7012 (N · Stephan Schann, PhD · Phase I and Phase II Clinical Trials in Progress

NCT06824155 · HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

Phase: EARLY_PHASE1 · Sponsor: Radiopharm Theranostics, Ltd · Enrollment: 30 · Start: 2025-02-12 · Primary completion: 2027-12

Conditions: HER2 Gene Mutation, Advanced Solid Tumors Interventions: 177Lu-RAD202 Countries: Australia

Cited in AACR 2026:

• AB#10079 · A first-in-class HER2-targeted radiopharmaceutical therapy: Initial findings fro · Dimitris Voliotis · First-in-Human Phase I Clinical Trials

NCT06840886 · A Study of PHST001 in Advanced Solid Tumors

Phase: PHASE1 · Sponsor: Pheast Therapeutics · Enrollment: 272 · Start: 2025-03-31 · Primary completion: 2029-04

Conditions: Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor Interventions: PHST001, Chemotherapy per Standard of Care Countries: United States

Cited in AACR 2026:

• AB#10269 · Initial results from a phase 1 study of PHST001, a macrophage activating anti-CD · Raphael Rousseau, MD;PhD · Phase 0 and First-in-Human Phase I Clinical Trials

NCT06856499 · Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficie

Phase: PHASE1 · Sponsor: University of Colorado, Denver · Enrollment: 50 · Start: 2025-12-08 · Primary completion: 2027-07

Conditions: Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer Interventions: Cirtuvivint, Olaparib Countries: United States

Cited in AACR 2026:

• AB#1779 · The pan-CLK DYRK inhibitor SM09419 prolongs animal survival times in a subset of · Xin (Alice) Zhai, PhD · Mechanistic Insights for Targeted Therapies in Pediatric Cancer

NCT06883747 · Clinical Trial of BMS-986504 in Recurrent GBM Patients

Phase: EARLY_PHASE1 · Sponsor: Nader Sanai · Enrollment: 9 · Start: 2025-04-28 · Primary completion: 2026-09-28

Conditions: Glioblastoma WHO Grade IV Interventions: BMS-986504 Countries: United States

Cited in AACR 2026:

• AB#10313 · ­A phase 0/1 study of PRMT5 inhibitor BMS-986504 in recurrent glioblastoma · An-Chi Tien, PhD · Phase 0 and First-in-Human Phase I Clinical Trials

NCT06888830 · A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ini

Phase: PHASE1, PHASE2 · Sponsor: Shanghai Junshi Bioscience Co., Ltd. · Enrollment: 374 · Start: 2025-04-11 · Primary completion: 2026-07-01

Conditions: Advanced Malignant Solid Tumours Interventions: JS212 for Injection Countries: China

Cited in AACR 2026:

• AB#10132 · Preliminary results from a first-in-human phase I/II study of JS212, an EGFR/HER · Wei Su · Phase 0 and First-in-Human Phase I Clinical Trials

NCT06888960 · Safety Study of CC312 in Autoimmune Disease Patients

Phase: EARLY_PHASE1 · Sponsor: CytoCares Inc · Enrollment: 18 · Start: 2024-11-08 · Primary completion: 2026-11-08

Conditions: Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA), Primary Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia Interventions: CC312 Countries: China

Cited in AACR 2026:

• AB#3675 · CC312, a novel CD19/CD3/CD28 tri-specific T cell engager, leads to rapid and dee · Xiaofang Zhang, PhD · Redefining Targeted Therapy: Bispecific T-Cell Engagers and Antibody-Drug Conjugates 2

NCT06893380 · Combination Therapy of GCNT and Tislelizumab in Advanced Biliary Tract Cancer

Sponsor: CHA University · Enrollment: 61 · Start: 2024-10-01 · Primary completion: 2026-05-08

Conditions: Locally Advanced Biliary Tract Cancers, Metastatic Biliary Tract Cancers Interventions: Gemcitabine, Cisplatin, Nab-paclitaxel, and Tislelizumab. Countries: South Korea

Cited in AACR 2026:

• AB#9728 · A phase 1b/2 trial of gemcitabine, cisplatin, nab-paclitaxel, and tislelizumab ( · Hong Jae Chon, MD · Phase I Clinical Trials in Progress

NCT06907043 · A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Soli

Phase: PHASE1, PHASE2 · Sponsor: Eikon Therapeutics · Enrollment: 130 · Start: 2025-04-30 · Primary completion: 2028-12

Conditions: Advanced Solid Tumors Interventions: EIK1004-001 (IMP1707-001) Countries: Australia, China, United States

Cited in AACR 2026:

• AB#9865 · A first-in-human (FIH), Phase 1/2, dose-escalation and dose-optimization study o · Meghal Gandhi · Phase I and Phase II Clinical Trials in Progress

NCT06922383 · A Clinical Study of Arfolitixorin in Patients With mCRC

Phase: PHASE1, PHASE2 · Sponsor: Isofol Medical AB · Enrollment: 60 · Start: 2025-04-10 · Primary completion: 2028-03-31

Conditions: Metastatic Colorectal Cancer (mCRC) Interventions: arfolitixorin (ARFOX + bevacizumab) Countries: Germany

Cited in AACR 2026:

• AB#9931 · Phase 1b/2 study of arfolitixorin in combination with 5-fluorouracil (5FU), oxal · Roger Tell, MD · Phase II and Phase III Clinical Trials in Progress

NCT06959706 · Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of T

Phase: PHASE1 · Sponsor: Tagworks Pharmaceuticals BV · Enrollment: 50 · Start: 2025-05-07 · Primary completion: 2026-09

Conditions: Advanced Solid Tumors Interventions: TGW101 Countries: United States

Cited in AACR 2026:

• AB#4905 · Characterization of TAG-72, a glycan-based ADC target and its pan-tumor expressi · Joseph Schonhoft, PhD · Biomarkers Predictive of Therapeutic Benefit 4

NCT06971523 · A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies

Phase: PHASE1, PHASE2 · Sponsor: CytosinLab Therapeutics Co., Ltd. · Enrollment: 224 · Start: 2024-12-25 · Primary completion: 2028-12-31

Conditions: Solid Tumor, Lymphoma Interventions: CTS3497 Countries: China

Cited in AACR 2026:

• AB#1874 · The MTA-cooperative PRMT5 inhibitor CTS3497 alone and in synergy with mechanism- · Yilin Liu, PhD · Epigenetic Modulators 1

NCT07007117 · PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Phase: PHASE1 · Sponsor: Stephan Grupp MD PhD · Enrollment: 38 · Start: 2025-06-20 · Primary completion: 2032-06-30

Conditions: Refractory Neuroblastoma, Relapsed Neuroblastoma, High-Risk Neuroblastoma Interventions: PHOX2B PC-CAR T Cells Countries: United States

Cited in AACR 2026:

• AB#1028 · Epitope-encoded mRNA-LNP vaccine to enhance anti-tumor potency and persistence o · Timothy Spear, MD;PhD · Immunotherapies in Pediatric Cancers
• AB#2003 · Evaluating TCR mimetic CAR T cell preclinical therapeutics in an immunocompetent · Elisabeth Posthill, BS;MS · Pediatric Cancer Models

NCT07032285 · Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas

Phase: PHASE2 · Sponsor: Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas · Enrollment: 25 · Start: 2025-01-15 · Primary completion: 2027-04-30

Conditions: Soft Tissue Sarcoma (STS) Interventions: Cirtuvivint Countries: Spain

Cited in AACR 2026:

• AB#1779 · The pan-CLK DYRK inhibitor SM09419 prolongs animal survival times in a subset of · Xin (Alice) Zhai, PhD · Mechanistic Insights for Targeted Therapies in Pediatric Cancer

NCT07141706 · A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors

Phase: PHASE1 · Sponsor: DualityBio Inc. · Enrollment: 233 · Start: 2025-09-23 · Primary completion: 2028-06

Conditions: Advanced/Metastatic Solid Tumors Interventions: DB-1317 Countries: Australia, United States

Cited in AACR 2026:

• AB#10379 · A Phase 1a/1b, first-in-human study of an ADC targeting ADAM9 (DB-1317) in parti · Charlotte Lemech, MBBS;MD · Phase I Clinical Trials in Progress

NCT07155200 · Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)

Phase: PHASE1, PHASE2 · Sponsor: Washington University School of Medicine · Enrollment: 42 · Start: 2025-12-18 · Primary completion: 2028-07-31

Conditions: Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Interventions: Cirtuvivint, Irinotecan Countries: United States

Cited in AACR 2026:

• AB#1779 · The pan-CLK DYRK inhibitor SM09419 prolongs animal survival times in a subset of · Xin (Alice) Zhai, PhD · Mechanistic Insights for Targeted Therapies in Pediatric Cancer

NCT07156253 · Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tu

Phase: PHASE1 · Sponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Enrollment: 110 · Start: 2025-08-26 · Primary completion: 2028-08-25

Conditions: Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer, BRCA 1 /2 and / or HRD, Advanced Solid Tumors Interventions: SYN818 and Olaparib will be administered Countries: China

Cited in AACR 2026:

• AB#9909 · Phase Ib study of POLQ inhibitor SYN818 combined with olaparib in advanced solid · Xuzhen Tang, PhD · Phase I and Phase II Clinical Trials in Progress

NCT07213791 · A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

Phase: PHASE1 · Sponsor: Eli Lilly and Company · Enrollment: 241 · Start: 2025-10-22 · Primary completion: 2028-07

Conditions: Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms Interventions: LY4337713 Countries: Germany, Japan, Netherlands, United States

Cited in AACR 2026:

• AB#10123 · FiREBOLT: A phase 1 study evaluating radioligand therapy with LY4337713 in adult · Gary Ulaner · Phase I Clinical Trials in Progress

NCT07213804 · A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum

Phase: PHASE3 · Sponsor: Eli Lilly and Company · Enrollment: 1080 · Start: 2025-10-22 · Primary completion: 2028-04

Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis Interventions: Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV Countries: Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark

Cited in AACR 2026:

• AB#623 · LY4170156, an antibody-drug conjugate targeting folate receptor alpha, exhibits · Zhaohai Lu, BS;MS · Engineering the Next Wave of Antibody-Based Cancer Therapeutics

NCT07230977 · GenSci139 in Patients With Advanced Solid Tumors

Phase: PHASE1 · Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. · Enrollment: 280 · Start: 2025-11-19 · Primary completion: 2028-07-07

Conditions: Advanced Solid Tumors Interventions: GenSci139 Countries: China

Cited in AACR 2026:

• AB#9721 · Towards a platform PBPK-QSP model for first-in-human dose selection of GenSci139 · Yehua Xie, PhD · Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2

NCT07251166 · A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of

Phase: PHASE1 · Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. · Enrollment: 170 · Start: 2025-12-10 · Primary completion: 2028-03

Conditions: Advanced Solid Tumors Interventions: GenSci140 for Injection Countries: China

Cited in AACR 2026:

• AB#9872 · Whole body PBPK/PD modeling to support first-in-human dose selection for GenSci1 · Yehua Xie, PhD · Late-Breaking Research: Bioinformatics, Computational Biology, Systems Biology, and Convergent Science 2

NCT07253662 · Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients With Peritoneal M

Phase: PHASE1 · Sponsor: Northwell Health · Enrollment: 10 · Start: 2026-12-30 · Primary completion: 2027-12-30

Conditions: Adenocarcinoma Pancreas Interventions: PIPAC, Nab-paclitaxel Countries: United States

Cited in AACR 2026:

• AB#10149 · Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in patients with pe · Julien Hohenleitner, MD · Phase I and Phase II Clinical Trials in Progress

NCT07281716 · Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC

Phase: PHASE1, PHASE2 · Sponsor: Dan Feng · Enrollment: 24 · Start: 2025-12-01 · Primary completion: 2028-12-15

Conditions: Metastatic Microsatellite Stable Colorectal Carcinoma Interventions: Nadunolimab, Toripalimab Countries: United States

Cited in AACR 2026:

• AB#9976 · A phase 1b/2 study of toripalimab and nadunolimab for the treatment of chemother · Jacob Lowy, BA;MD · Phase I Clinical Trials in Progress

NCT07284186 · First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

Phase: PHASE1 · Sponsor: Plexium, Inc. · Enrollment: 155 · Start: 2025-12-01 · Primary completion: 2029-12

Conditions: Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Metastatic Solid Tumor, Non-Small Cell Lung Carcinoma Interventions: PLX-61639 Countries: United States

Cited in AACR 2026:

• AB#10124 · A Phase 1, first-in-human study of the SMARCA2 degrader, PLX-61639, in patients · Jorge DiMartino, MD;PhD · Phase I Clinical Trials in Progress

ACTIVE_NOT_RECRUITING (21)

NCT03152318 · A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

Phase: PHASE1 · Sponsor: Dana-Farber Cancer Institute · Enrollment: 62 · Start: 2017-07-18 · Primary completion: 2027-01

Conditions: Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma Interventions: rQNestin, Cyclophosphamide, Stereotactic biopsy Countries: United States

Cited in AACR 2026:

• AB#554 · Pre-existing T cells drive durable anti-tumor immunity after oncolytic virus the · Maxime Meylan, PhD · Immune Response to Therapies

NCT03433469 · Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Can

Phase: PHASE2 · Sponsor: University of California, San Francisco · Enrollment: 27 · Start: 2018-07-31 · Primary completion: 2023-01-31

Conditions: Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer Interventions: Osimertinib, Therapeutic Conventional Surgery Countries: United States

Cited in AACR 2026:

• AB#4952 · Spatial transcriptomics reveals distinct SPP1-CD44 signaling networks in neoadju · Whitney Tamaki, BS;MS;PhD · Spatial Proteomics and Transcriptomics 1

NCT03873805 · PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate

Phase: PHASE1 · Sponsor: City of Hope Medical Center · Enrollment: 14 · Start: 2019-08-20 · Primary completion: 2022-08-20

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8 Interventions: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes, Cyclophosphamide, Fludarabine, Fludarabine Phosphate Countries: United States

Cited in AACR 2026:

• AB#8100 · Single-cell liquid biopsy profiling in mCRPC receiving PSCA-targeted CAR-T cell · Doanna Pham, BS · Biomarkers Predictive of Therapeutic Benefit 4

NCT04180371 · Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Phase: PHASE1, PHASE2 · Sponsor: BicycleTx Limited · Enrollment: 288 · Start: 2019-11-07 · Primary completion: 2026-07-31

Conditions: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer Interventions: BT5528, Nivolumab Countries: Belgium, South Korea, Spain, United Kingdom, United States

Cited in AACR 2026:

• AB#11073 · An EphA2-targeting Bicycle Drug Conjugate (BDC), BT5528, in combination with niv · Babar Bashir, MD · First-in-Human Phase I Clinical Trials

NCT04395677 · A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Phase: PHASE2 · Sponsor: Nuvation Bio Inc. · Enrollment: 173 · Start: 2020-07-07 · Primary completion: 2024-06-07

Conditions: Non Small Cell Lung Cancer Interventions: AB-106 Countries: China

Cited in AACR 2026:

• AB#9878 · Taletrectinib in tyrosine kinase inhibitor (TKI)-pretreated patients with ROS1+ · Geoffrey Liu, MD · Phase II Clinical Trials

NCT04561362 · Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Phase: PHASE1, PHASE2 · Sponsor: BicycleTx Limited · Enrollment: 329 · Start: 2020-07-17 · Primary completion: 2026-03

Conditions: Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms Interventions: BT8009, Pembrolizumab Countries: Canada, France, Italy, Spain, United Kingdom, United States

Cited in AACR 2026:

• AB#3878 · NECTIN4-amplified breast cancer targeted by Zelenectide Pevedotin: Amplif · Alexander Azizi, BA;MA;MS · Tumor Diagnostics, Prognostics, and Therapeutic Outcomes

NCT04707248 · A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors

Phase: PHASE1 · Sponsor: Daiichi Sankyo · Enrollment: 179 · Start: 2020-12-22 · Primary completion: 2026-04-30

Conditions: Renal Cell Carcinoma, Ovarian Tumor Interventions: DS-6000a, DS-6000a Countries: Japan, United States

Cited in AACR 2026:

• AB#367 · Pharmacokinetic-tumor growth inhibition modeling of raludotatug deruxtecan (R-DX · YoungJun Yoo, Pharm D · Quantitative Pharmacology and Translational Modeling

NCT04919811 · Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

Phase: PHASE2 · Sponsor: Nuvation Bio Inc. · Enrollment: 217 · Start: 2021-09-01 · Primary completion: 2025-06-11

Conditions: Non Small Cell Lung Cancer Interventions: Taletrectinib Countries: Canada, China, France, Italy, Japan, Poland, South Korea, Spain

Cited in AACR 2026:

• AB#9878 · Taletrectinib in tyrosine kinase inhibitor (TKI)-pretreated patients with ROS1+ · Geoffrey Liu, MD · Phase II Clinical Trials

NCT04995523 · A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced

Phase: PHASE1, PHASE2 · Sponsor: AstraZeneca · Enrollment: 212 · Start: 2021-09-14 · Primary completion: 2026-08-28

Conditions: Non-Small-Cell Lung Carcinoma Interventions: AZD2936 Countries: Australia, Belgium, Brazil, China, Denmark, France, Georgia, Japan

Cited in AACR 2026:

• AB#7143 · Rilvegostomig elicits greater immune activation and tumor inhibition than clinic · Jun Ren · Bi- and Tri-Specific Antibody Therapies

NCT05168423 · CART-EGFR-IL13Ra2 in EGFR Amplified Recurrent GBM

Phase: PHASE1 · Sponsor: University of Pennsylvania · Enrollment: 67 · Start: 2023-02-24 · Primary completion: 2039-12-19

Conditions: Glioblastoma Interventions: CART-EGFR-IL13Ra2 Cells Countries: United States

Cited in AACR 2026:

• AB#8445 · Spatial profiling of recurrent glioblastoma in a Phase I clinical trial reveals · Wesley Wilson · Microenvironmental Determinants of Therapy Response and Resistance 1

NCT05283109 · ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM

Phase: PHASE1 · Sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP · Enrollment: 24 · Start: 2023-08-30 · Primary completion: 2025-04-11

Conditions: Glioma, Malignant Interventions: Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine, Hiltonol Countries: United States

Cited in AACR 2026:

• AB#6861 · Peptide-based tumor-associated antigen vaccine in glioblastoma: Correlative resu · Elizabeth Owens, BS · Clinical Correlates of Immunotherapy

NCT05327270 · Non-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignan

Phase: PHASE1 · Sponsor: M.D. Anderson Cancer Center · Enrollment: 18 · Start: 2022-09-13 · Primary completion: 2027-02-02

Conditions: Head and Neck Cancer Interventions: Nivolumab Countries: United States

Cited in AACR 2026:

• AB#10242 · Intralesional PD-1 blockade for oral cancer prevention: First-in-class phase 1 t · Moran Amit, MD;PhD · Phase I Clinical Trials

NCT05547061 · A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor

Phase: PHASE1, PHASE2 · Sponsor: Cellbion Co., Ltd. · Enrollment: 91 · Start: 2021-04-12 · Primary completion: 2024-12-31

Conditions: Prostate Cancer, mCRPC Interventions: Lu-177-DGUL, Ga-68-NGUL Countries: South Korea

Cited in AACR 2026:

• AB#10186 · Safety, dosimetry, and RP2D determination of Ga‑68‑NGUL and Lu&#8209 · Seung-hwan Jeong, MD;PhD · Phase II and Phase III Clinical Trials

NCT05565417 · Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphom

Phase: PHASE1, PHASE2 · Sponsor: Immunitas Therapeutics · Enrollment: 67 · Start: 2022-11-28 · Primary completion: 2026-01

Conditions: Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Small Bowel Cancer Interventions: IMT-009, Fruquintinib Countries: United States

Cited in AACR 2026:

• AB#10063 · A first in human, dose escalation (DE) and biomarker cohort expansion (BCE) of I · Susanna Ulahannan, MD · First-in-Human Phase I Clinical Trials

NCT05599984 · Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Throu

Phase: PHASE1 · Sponsor: AbbVie · Enrollment: 288 · Start: 2022-12-05 · Primary completion: 2026-06

Conditions: Advanced Solid Tumors Interventions: ABBV-706, Cisplatin, Budigalimab, Carboplatin Countries: Australia, China, France, Germany, Israel, Italy, Japan, South Korea

Cited in AACR 2026:

• AB#4535 · Efficacy of ABBV-706, a SEZ6-targeted topoisomerase 1 inhibitor ADC: A report fr · Elizabeth Stewart, MD · Immunotherapies in Pediatric Cancers

NCT05614102 · A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose

Phase: PHASE1 · Sponsor: Bayer · Enrollment: 284 · Start: 2022-11-04 · Primary completion: 2026-05-21

Conditions: Advanced Solid Tumors Interventions: BAY2965501, Pembrolizumab, Platinum-based Chemotherapy Countries: Belgium, China, Japan, South Korea, Spain, United Kingdom, United States

Cited in AACR 2026:

• AB#11061 · First in human trial of BAY2965501, a selective inhibitor of intra-cellular T ce · Jason Henry, MD · Phase 0 and First-in-Human Phase I Clinical Trials

NCT05886920 · A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With

Phase: PHASE1, PHASE2 · Sponsor: D3 Bio (Wuxi) Co., Ltd · Enrollment: 67 · Start: 2023-07-10 · Primary completion: 2028-04

Conditions: Advanced Solid Tumors With MAPK Pathway Mutations Interventions: D3S-002, D3S-001 Countries: Australia, China, United States

Cited in AACR 2026:

• AB#10598 · First in human phase 1 study of D3S-002, a purposely designed ERK1/2 inhibitor, · Shaonan Wang, B Eng;MBA;MS;PhD · First-in-Human Phase I Clinical Trials

NCT05990543 · Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer

Phase: PHASE1, PHASE2 · Sponsor: Korea University Anam Hospital · Enrollment: 59 · Start: 2024-01-29 · Primary completion: 2025-12-01

Conditions: Recurrent or Metastatic Colorectal Cancer Interventions: Nelmastobart and Capecitabine Countries: South Korea

Cited in AACR 2026:

• AB#7007 · Biomarkers of nelmastobart efficacy: BTN1A1 expression and tumor microenvironmen · Stephen Yoo, PhD · Biomarkers Predictive of Therapeutic Benefit 6

NCT06237881 · A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to In

Phase: PHASE1, PHASE2 · Sponsor: M.D. Anderson Cancer Center · Enrollment: 15 · Start: 2024-01-31 · Primary completion: 2027-01-01

Conditions: Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms Interventions: KSQ-001EX, Interleukin-2, Cyclophosphamide, Fludarabine Countries: United States

Cited in AACR 2026:

• AB#4493 · Anti-tumor function and long-term persistence of KSQ-001EX, a SOCS1-edited eTIL& · Dipen Sangurdekar, MBA;PhD · Adoptive Cell Therapy 1

NCT06268015 · Botensilimab and Balstilimab Optimization in Colorectal Cancer

Phase: PHASE2 · Sponsor: Nicholas DeVito, MD · Enrollment: 16 · Start: 2024-11-18 · Primary completion: 2028-07

Conditions: Colorectal Cancer Interventions: Botensilimab, Balstilimab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab Countries: United States

Cited in AACR 2026:

• AB#10589 · Preliminary results of first-line botensilimab (BOT) and balstilimab (BAL) optim · Nicholas DeVito, MD · Phase I Clinical Trials

NCT06840483 · Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

Phase: PHASE2 · Sponsor: BicycleTx Limited · Enrollment: 66 · Start: 2025-03-03 · Primary completion: 2028-06-30

Conditions: Breast Cancer Interventions: Zelenectide pevedotin (BT8009) Countries: Australia, Belgium, France, Italy, Spain, United Kingdom, United States

Cited in AACR 2026:

• AB#3878 · NECTIN4-amplified breast cancer targeted by Zelenectide Pevedotin: Amplif · Alexander Azizi, BA;MA;MS · Tumor Diagnostics, Prognostics, and Therapeutic Outcomes

NOT_YET_RECRUITING (8)

NCT06621615 · Clinical Study of CVL006 Injection in Advanced Solid Tumors

Phase: PHASE1 · Sponsor: Convalife (Shanghai) Co., Ltd. · Enrollment: 120 · Start: 2024-11-20 · Primary completion: 2028-05-20

Conditions: Advanced Solid Tumor Interventions: CVL006 Injection

Cited in AACR 2026:

• AB#6173 · An open-label, multicenter Phase I clinical study of CVL006, a novel PD-L1/VEGF · Steve Shen, PhD · Targeted Antigen Therapies and Immunity

NCT06894407 · Intratumoral Targeted Hyperthermia Therapy (THT) for Stage 3C/3D/4M1 Cutaneous Metastatic

Phase: NA · Sponsor: Sona Nanotech Inc · Enrollment: 10 · Start: 2025-05 · Primary completion: 2026-04

Conditions: Cutaneous Metastatic Melanoma Interventions: Device: Targeted Hyperthermia Therapy

Cited in AACR 2026:

• AB#9747 · Targeted hyperthermia induces immunogenic tumor remodeling and demonstrates earl · Carman Giacomantonio, MD · First-in-Human Phase I Clinical Trials

NCT06934590 · Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC

Phase: PHASE1 · Sponsor: GeneCraft Inc. · Enrollment: 18 · Start: 2025-05 · Primary completion: 2026-09

Conditions: Non-Small Cell Lung Cancer Interventions: RX001 Countries: South Korea

Cited in AACR 2026:

• AB#9850 · A first-in-human, intra-tumoral AAV2-RUNX3 gene therapy (RX001) for advan · Kyoungmi Jung, PhD · Phase I Clinical Trials in Progress

NCT07088588 · Study of SYN608 for the Treatment of Advanced or Metastatic Solid Tumors

Phase: PHASE1 · Sponsor: Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Enrollment: 105 · Start: 2025-07-31 · Primary completion: 2028-07-31

Conditions: Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer, BRCA Mutation, HRR Deficiency Interventions: SYN608 Countries: China

Cited in AACR 2026:

• AB#9905 · First-in-human study of oral PARG inhibitor SYN608 in advanced solid tumors · Xuzhen Tang, PhD · Phase I and Phase II Clinical Trials in Progress

NCT07138001 · Phase 2 Clinical Trial of KH617

Phase: PHASE2 · Sponsor: Sichuan Honghe Biotechnology Co., Ltd. · Enrollment: 60 · Start: 2025-08 · Primary completion: 2027-09

Conditions: Recurrent Glioblastoma Interventions: KH617+TMZ, KH617, TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16

Cited in AACR 2026:

• AB#10138 · The natural compound KH617 reverses glioblastoma resistance to alkylating agents · Yun Feng, BSc, MSc, PhD · Late-Breaking Research: Chemistry
• AB#10634 · Broad-spectrum antitumor activity of the biosynthetically derived molecule KHN70 · Yun Feng, BSc, MSc, PhD · Late-Breaking Research: Chemistry

NCT07157956 · CVL006 Combination Therapy in Advanced Solid Tumors

Phase: PHASE1, PHASE2 · Sponsor: Convalife (Shanghai) Co., Ltd. · Enrollment: 318 · Start: 2025-09-10 · Primary completion: 2028-08-12

Conditions: Advanced Solid Tumor Interventions: CVL006 combined with pemetrexed and carboplatin, CVL006 in combination with SKB264, CVL006 in combination with DS-8201, CVL006 in combination with Enfortumab Vedotin Countries: China

Cited in AACR 2026:

• AB#9848 · Phase I/II clinical trial of CVL006 combination therapy in advanced solid tumors · Steve Shen, PhD · Phase I Clinical Trials in Progress

NCT07198321 · A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With

Phase: PHASE1, PHASE2 · Sponsor: Genfleet Therapeutics (Shanghai) Inc. · Enrollment: 450 · Start: 2025-09-22 · Primary completion: 2027-09-22

Conditions: Cancer, PDAC, CRC (Colorectal Cancer), NSCLC Interventions: GFH276 Countries: China

Cited in AACR 2026:

• AB#3321 · Preclinical evaluation of GFH276 monotherapy and combination therapy for RAS-mut · Feng Yan, PhD · Novel Antitumor Agents 2

NCT07263594 · A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors

Phase: PHASE1, PHASE2 · Sponsor: DualityBio Inc. · Enrollment: 127 · Start: 2025-12 · Primary completion: 2028-12

Conditions: Gastrointestinal Cancer Interventions: DB-1324 Countries: Australia, United States

Cited in AACR 2026:

• AB#10143 · A phase 1/2, first-in-human study of an ADC targeting CDH17 (DB-1324) in partici · Joe Wei, MBBS, FRACP, PhD · Phase I Clinical Trials in Progress

COMPLETED (15)

NCT01417546 · NHS-IL12 for Solid Tumors

Phase: PHASE1 · Sponsor: National Cancer Institute (NCI) · Enrollment: 72 · Start: 2011-12-12 · Primary completion: 2021-06-02

Conditions: Epithelial Neoplasms, Malignant, Epithelial Tumors, Malignant, Malignant Mesenchymal Tumor Interventions: NHS-IL-12 Countries: United States

Cited in AACR 2026:

• AB#4025 · A tumor-targeting IL-12 immunocytokine therapy increases peripheral natural kill · Stephanie Pitts, PhD · Immune Response to Therapies

NCT01784913 · A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer

Phase: PHASE1, PHASE2 · Sponsor: Ultimovacs ASA · Enrollment: 22 · Start: 2013-04-15 · Primary completion: 2015-07-08

Conditions: Prostate Cancer Interventions: UV1 synthetic peptide vaccine and GM-CSF Countries: Norway

Cited in AACR 2026:

• AB#3680 · Mapping immune clonotypes in prostate cancer using spatial V(D)J to resolve canc · Eirik Høye, BS;MS;PhD · Microenvironmental Determinants of Therapy Response and Resistance 2

NCT01968109 · An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectivene

Phase: PHASE1, PHASE2 · Sponsor: Bristol-Myers Squibb · Enrollment: 1482 · Start: 2013-11-05 · Primary completion: 2024-05-22

Conditions: Neoplasms by Site Interventions: Relatlimab, Nivolumab, BMS-986213 Countries: Australia, Austria, Canada, Denmark, Finland, France, Germany, Italy

Cited in AACR 2026:

• AB#11152 · Dose escalation and expansion of nivolumab plus relatlimab (NIVO + RELA) in soli · Takekazu Aoyama, MD;PhD · Late-Breaking Research: Clinical Research 4

NCT02719977 · A Phase I Study of CX5461

Phase: PHASE1 · Sponsor: Canadian Cancer Trials Group · Enrollment: 41 · Start: 2016-06-13 · Primary completion: 2020-01-30

Conditions: Cancer Interventions: CX5461 Countries: Canada

Cited in AACR 2026:

• AB#10408 · Pilot study of pidnarulex pharmacodynamics in patients with advanced solid tumor · Jibran Ahmed, MD · Phase I and Phase II Clinical Trials in Progress

NCT02859857 · Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors

Phase: PHASE1 · Sponsor: Bexion Pharmaceuticals, Inc. · Enrollment: 86 · Start: 2016-09-01 · Primary completion: 2019-06-17

Conditions: Neoplasms Interventions: BXQ-350 Countries: United States

Cited in AACR 2026:

• AB#3974 · BXQ-350 reduces incidence, severity, and time to on-set of chemotherapy induced · Gilles Tapolsky, MBA;PhD · Metabolism and Microbiome in Cancer Initiation and Prevention

NCT03056339 · Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Phase: PHASE1, PHASE2 · Sponsor: M.D. Anderson Cancer Center · Enrollment: 49 · Start: 2017-06-21 · Primary completion: 2023-03-06

Conditions: B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Non-hodgkin Lymphoma Interventions: Fludarabine, Cyclophosphamide, Mesna, iC9/CAR.19/IL15-Transduced CB-NK Cells, AP1903 Countries: United States

Cited in AACR 2026:

• AB#300 · Selecting cord blood-derived NK cells enriched in mature subsets optimizes CAR-N · Ye Ethan Li, MD;PhD · Alternative Cell Type and in Situ Cell Therapies

NCT03340935 · Safety, Feasibility and Metabolic Effects of the Fasting Mimicking Diet (FMD) in Cancer Pa

Phase: NA · Sponsor: Filippo de Braud · Enrollment: 101 · Start: 2017-02-01 · Primary completion: 2020-07-30

Conditions: Malignant Neoplasm, Cancer Interventions: Fasting mimicking diet Countries: Italy

Cited in AACR 2026:

• AB#5938 · Fasting induces ferroptosis by modulating lipid metabolism in breast cancer · Claudio Vernieri, MD;PhD · Metabolic Regulation in Breast and Gynecologic Cancers

NCT03604692 · A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD

Phase: PHASE1, PHASE2 · Sponsor: Syndax Pharmaceuticals · Enrollment: 41 · Start: 2018-11-01 · Primary completion: 2022-08-12

Conditions: Chronic Graft-versus-host-disease Interventions: axatilimab Countries: United States

Cited in AACR 2026:

• AB#542 · Combined anti-CSF-1R and anti-TIM-3 overcome macrophage-mediated mechanisms of P · Adam Nelson, PhD · Novel Strategies to Reverse Drug Resistance

NCT03750786 · A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 F

Phase: PHASE3 · Sponsor: Isofol Medical AB · Enrollment: 490 · Start: 2018-12-18 · Primary completion: 2022-11-18

Conditions: Colo-rectal Cancer Interventions: Arfolitixorin, Leucovorin Countries: Australia, Austria, Canada, France, Germany, Greece, Japan, Spain

Cited in AACR 2026:

• AB#9931 · Phase 1b/2 study of arfolitixorin in combination with 5-fluorouracil (5FU), oxal · Roger Tell, MD · Phase II and Phase III Clinical Trials in Progress

NCT03805594 · 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant

Phase: PHASE1 · Sponsor: University of California, San Francisco · Enrollment: 43 · Start: 2019-05-10 · Primary completion: 2024-01-10

Conditions: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer, Stage IVA Prostate Cancer Interventions: Lutetium Lu 177-PSMA-617, Pembrolizumab Countries: United States

Cited in AACR 2026:

• AB#1731 · Multi-omic single-cell assessment of castration-resistant prostate cancer patien · Anusha Muralidhar, MS;PhD · Immunomodulatory Effects of Targeted Therapies

NCT05025358 · A Study of LP-118 in Patients With Advanced Tumors

Phase: PHASE1 · Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. · Enrollment: 68 · Start: 2021-09-08 · Primary completion: 2025-07-09

Conditions: Solid Tumor, Lymphoma, Non-Hodgkin Interventions: LP-118 tablet Countries: China

Cited in AACR 2026:

• AB#9636 · The first report of patients with solid tumors treated with LP-118, a novel Bcl- · Qing Zhou · Phase I Clinical Trials

NCT05582850 · DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours

Phase: PHASE1 · Sponsor: Domain Therapeutics SA · Enrollment: 29 · Start: 2022-11-24 · Primary completion: 2025-04-08

Conditions: Solid Tumor, Adult Interventions: DT-9081 - dose escalation, DT-9081 - expansion Countries: Belgium, France

Cited in AACR 2026:

• AB#1978 · Biomarker dynamics in the completed phase I study of DT-9081: An analysis of · Stephan Schann, PhD · Biomarkers Predictive of Therapeutic Benefit 5

NCT05858164 · A First-in-human Study to Learn How Safe the Study Treatment BAY2862789 is, to Find the Be

Phase: PHASE1 · Sponsor: Bayer · Enrollment: 45 · Start: 2023-08-07 · Primary completion: 2025-09-26

Conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer Interventions: BAY2862789 Countries: Australia, China, Israel, South Korea, Spain, United States

Cited in AACR 2026:

• AB#10693 · Global first-in-human (FiH) monotherapy dose escalation trial of BAY2862789, a d · Shirish Madhav Gadgeel, Unknown · Phase 0 and First-in-Human Phase I Clinical Trials

NCT05908773 · A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors

Phase: EARLY_PHASE1 · Sponsor: TransCode Therapeutics · Enrollment: 1 · Start: 2023-04-04 · Primary completion: 2023-08-23

Conditions: Advanced Solid Tumor Interventions: TTX-MC138-NODAGA-Cu64 Countries: United States

Cited in AACR 2026:

• AB#10103 · Phase 1 clinical trial of a first-in-class antagomir therapeutic against advance · Zdravka Medarova, BA;PhD · Phase I Clinical Trials

NCT06667765 · A Study of RPT1G After Single and Multiple Doses in Healthy Adult Participants

Phase: PHASE1 · Sponsor: Remedy Plan, Inc. · Enrollment: 56 · Start: 2024-11-18 · Primary completion: 2025-05-14

Conditions: Healthy Interventions: RPT1G, Placebo Countries: Australia

Cited in AACR 2026:

• AB#2586 · RPT1G, a novel hyperbolic NAMPT inhibitor, effectively synergizes with PARP inhi · Parisa Moghaddam-Taaheri · Novel Targets and Pathways

SUSPENDED (1)

NCT06763341 · A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Phase: PHASE1 · Sponsor: City of Hope Medical Center · Enrollment: 12 · Start: 2025-07-30 · Primary completion: 2027-01-16

Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, PCNA Inhibitor AOH1996, Venetoclax Countries: United States

Cited in AACR 2026:

• AB#7656 · Development of hydrophilic and metabolically stable heterocyclic AOH1996 analogu · Pouya Haratipour, PhD · New Ligands and Inhibitors

TERMINATED (6)

NCT02706353 · APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma

Phase: PHASE1, PHASE2 · Sponsor: M.D. Anderson Cancer Center · Enrollment: 34 · Start: 2017-06-02 · Primary completion: 2025-03-10

Conditions: Melanoma Interventions: APX005M, Pembrolizumab Countries: United States

Cited in AACR 2026:

• AB#10130 · Intratumoral sotigalimab with pembrolizumab induces rapid activation of antigen · Salah Eddine Bentebibel, PhD · Phase II Clinical Trials

NCT03355066 · A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subje

Phase: PHASE1 · Sponsor: Biosplice Therapeutics, Inc. · Enrollment: 82 · Start: 2017-11-06 · Primary completion: 2022-11-14

Conditions: Solid Tumor, Adult Interventions: SM08502 Countries: United States

Cited in AACR 2026:

• AB#1779 · The pan-CLK DYRK inhibitor SM09419 prolongs animal survival times in a subset of · Xin (Alice) Zhai, PhD · Mechanistic Insights for Targeted Therapies in Pediatric Cancer

NCT05084859 · A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Admini

Phase: PHASE1 · Sponsor: Biosplice Therapeutics, Inc. · Enrollment: 30 · Start: 2021-11-03 · Primary completion: 2022-10-20

Conditions: Castration-resistant Prostate Cancer, Non-small Cell Lung Cancer, Colorectal Cancer Interventions: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab Countries: Australia, United States

Cited in AACR 2026:

• AB#1779 · The pan-CLK DYRK inhibitor SM09419 prolongs animal survival times in a subset of · Xin (Alice) Zhai, PhD · Mechanistic Insights for Targeted Therapies in Pediatric Cancer

NCT05220098 · First-in-Human Study of TAK-280 in Participants With Solid Tumors

Phase: PHASE1, PHASE2 · Sponsor: Takeda · Enrollment: 69 · Start: 2022-04-22 · Primary completion: 2025-07-28

Conditions: Unresectable Locally Advanced or Metastatic Cancer Interventions: TAK-280 Countries: Australia, Canada, Spain, United States

Cited in AACR 2026:

• AB#2255 · QSP modeling to inform dose and regimen selection for TAK-280: A bi-specific ant · AGNISH DEY · Quantitative Pharmacology and Translational Modeling

NCT05381909 · A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With So

Phase: PHASE1 · Sponsor: BeiGene · Enrollment: 157 · Start: 2022-07-06 · Primary completion: 2025-07-25

Conditions: Solid Tumor, Adult Interventions: BGB-24714, Paclitaxel, Carboplatin, Docetaxel Countries: Australia, China, New Zealand, South Korea, United States

Cited in AACR 2026:

• AB#10266 · A phase 1 study of BGB-24714, a second mitochondrial-derived activator of caspas · Hua-Xin Gao · Phase 0 and First-in-Human Phase I Clinical Trials
• AB#10273 · Pharmacodynamic (PD) characterization of BGB-24714, a second mitochondrial-deriv · Fernando Donate · Phase 0 and First-in-Human Phase I Clinical Trials

NCT05494866 · A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage o

Phase: PHASE1 · Sponsor: German Cancer Research Center · Enrollment: 6 · Start: 2022-12-07 · Primary completion: 2024-03-15

Conditions: CYP3A Inhibitor, Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Neoplasm Interventions: Cobicistat Oral Tablet, Gemcitabin, Nab paclitaxel Countries: Germany

Cited in AACR 2026:

• AB#10692 · Pulmonary toxicity associated with increased 6-OH-paclitaxel exposure in pancrea · Nicolas Hohmann, MD · Phase I Clinical Trials

UNKNOWN (8)

NCT02894853 · Lung Cancer Early Molecular Assessment Trial

Sponsor: The Netherlands Cancer Institute · Enrollment: 1297 · Start: 2016-06 · Primary completion: 2019-06

Conditions: Carcinoma, Non-Small-Cell Lung Interventions: Liquid (blood) biopsies and tumor biopsy (optional) Countries: Netherlands

Cited in AACR 2026:

• AB#3823 · Lung cancer subtyping using cell-free DNA fragmentomes and protein biomarkers · Jamie Medina · Liquid Biopsies: Circulating Nucleic Acids 1

NCT03454282 · Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial

Phase: NA · Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Enrollment: 100 · Start: 2018-07-01 · Primary completion: 2020-05-30

Conditions: Breast Cancer, Melanoma, Malignant Interventions: FMD Countries: Italy

Cited in AACR 2026:

• AB#5938 · Fasting induces ferroptosis by modulating lipid metabolism in breast cancer · Claudio Vernieri, MD;PhD · Metabolic Regulation in Breast and Gynecologic Cancers

NCT04248998 · Calorie Restriction With or Without Metformin in Triple Negative Breast Cancer

Phase: PHASE2 · Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Enrollment: 30 · Start: 2020-05-05 · Primary completion: 2024-05-01

Conditions: Triple-negative Breast Cancer Interventions: Fasting-mimicking diet, Metformin, Preoperative chemotherapy Countries: Italy

Cited in AACR 2026:

• AB#5938 · Fasting induces ferroptosis by modulating lipid metabolism in breast cancer · Claudio Vernieri, MD;PhD · Metabolic Regulation in Breast and Gynecologic Cancers

NCT04714827 · Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory

Phase: PHASE1, PHASE2 · Sponsor: Shanxi Province Cancer Hospital · Enrollment: 24 · Start: 2021-01-22 · Primary completion: 2024-09-30

Conditions: Multiple Myeloma Interventions: KQ-2003 CAR-T cells Countries: China

Cited in AACR 2026:

• AB#10291 · First in India, phase 1/2 study of an indigenously adapted, cost-efficient autol · Uday Surampudi, MBA;M Pharm · Phase II Clinical Trials

NCT05278975 · Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic So

Phase: PHASE1, PHASE2 · Sponsor: RS Oncology LLC · Enrollment: 186 · Start: 2022-03-31 · Primary completion: 2025-04-01

Conditions: Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant Interventions: RSO-021 Countries: United Kingdom

Cited in AACR 2026:

• AB#5238 · The first-in-class covalent peroxiredoxin 3 (PRX3) inhibitor RSO-021 modulates i · Brian Cunniff, PhD · Multi-Axis Antineoplastic Agents

NCT05824663 · A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects Wi

Phase: PHASE1 · Sponsor: Harbour BioMed US, Inc. · Enrollment: 50 · Start: 2023-05 · Primary completion: 2024-12

Conditions: Advanced Solid Tumor Interventions: HBM1020

Cited in AACR 2026:

• AB#8324 · Investigating the transcriptomic signature of B7-H7-mediated activation of NK ce · Michael Gomez, BA · Immune Checkpoint Blockade

NCT06223646 · A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple My

Phase: PHASE1, PHASE2 · Sponsor: Novatim Immune Therapeutics (Zhejiang) Co., Ltd. · Enrollment: 29 · Start: 2024-01-11 · Primary completion: 2026-03-31

Conditions: Multiple Myeloma Interventions: KQ-2003 CAR T-cells Countries: China

Cited in AACR 2026:

• AB#10291 · First in India, phase 1/2 study of an indigenously adapted, cost-efficient autol · Uday Surampudi, MBA;M Pharm · Phase II Clinical Trials

NCT06405685 · Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis

Phase: PHASE2 · Sponsor: Tianjin Medical University Cancer Institute and Hospital · Enrollment: 30 · Start: 2023-04-27 · Primary completion: 2025-10-30

Conditions: Pancreatic Cancer Interventions: Nimotuzumab, AG Countries: China

Cited in AACR 2026:

• AB#1552 · CXCR4/LITAF as predictive biomarkers for nimotuzumab plus AG therapy in pancreat · hao wang · Biomarkers Predictive of Therapeutic Benefit 2